Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1998-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/JCEM.83.8.5034PMID 9709955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.

  1997cited by this paper
• UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue.

  1997cited by this paper
• The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene*

  1997cited by this paper
• PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects.

  1997cited by this paper
• PPAR-γ Gene Expression Is Elevated in Skeletal Muscle of Obese and Type II Diabetic Subjects

  1997cited by this paper
• Regulation of Peroxisome Proliferator-activated Receptor γ Activity by Mitogen-activated Protein Kinase*

  1997cited by this paper
• The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

  1996cited by this paper
• Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes.

  1996cited by this paper
• Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects. Biochemical and molecular mechanisms.

  1996cited by this paper
• Adipogenesis and obesity: rounding out the big picture.

  1996cited by this paper
• Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2.

  1996cited by this paper
• Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.

  1996cited by this paper
• The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.

  1996cited by this paper
• Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

  1996cited by this paper
• The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones

  1996cited by this paper
• Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression.

  1996cited by this paper
• Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2

  1996cited by this paper
• Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes

  1996cited by this paper
• Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents.

  1995cited by this paper
• Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes.

  1995cited by this paper
• An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

  1995cited by this paper
• Fatty acid transport and fatty acid-binding proteins

  1995cited by this paper
• Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha.

  1995cited by this paper
• An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*)

  1995cited by this paper
• Thiazolidinediones and Fatty Acids Convert Myogenic Cells into Adipose-like Cells (*)

  1995cited by this paper
• Insulin Action and Glucose Metabolism in Nondiabetic Control and NIDDM Subjects: Comparison Using Human Skeletal Muscle Cell Cultures

  1995cited by this paper
• The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression.

  1994cited by this paper
• Troglitazone Prevents Glucose-Induced Insulin Resistance of Insulin Receptor in Rat-1 Fibroblasts

  1994cited by this paper
• Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

  1994cited by this paper
• Copyright � 1995, American Society for Microbiology PPAR�2 Regulates Adipose Expression of the

  1994cited by this paper
• The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability.

  1993cited by this paper
• Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

  1992cited by this paper
• Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in noninsulin-dependent diabetic subjects. Effects of insulin therapy.

  1991cited by this paper
• Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats

  1988cited by this paper
• Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

  1979cited by this paper

• A double-blinded, randomized, placebo-controlled study evaluating the impact of dates vinegar consumption on blood biochemical and hematological parameters in patients with type 2 diabetes

  2019cites this paper
• Effets de deux modalités d'entraînement et d'une complémentation à base d'extraits végétaux sur le développement du diabète de type 2 : Physiologie

  2018cites this paper
• adipose tissue protein gene expression in 3T3-L1 adipocytes and rat Modulation of carbohydrate response element-binding

  2016cites this paper
• Therapeutic effects of soluble dietary fiber consumption on type 2 diabetes mellitus.

  2016cites this paper
• Oral administration of green algae, Euglena gracilis, inhibits hyperglycemia in OLETF rats, a model of spontaneous type 2 diabetes.

  2016cites this paper
• Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes

  2016cites this paper
• Nutritional and functional properties of oats: An update

  2014cites this paper
• Polysaccharides immobilized in polypyrrole matrices are able to induce osteogenic differentiation in mouse mesenchymal stem cells

  2014cites this paper
• Treatment of metabolic syndrome with ankaflavin, a secondary metabolite isolated from the edible fungus Monascus spp.

  2014cites this paper
• Available online at www.jibresearch.com

  2014cites this paper
• Application of cell co-culture system to study fat and muscle cells

  2014cites this paper
• Monascin improves diabetes and dyslipidemia by regulating PPARγ and inhibiting lipogenesis in fructose-rich diet-induced C57BL/6 mice.

  2013cites this paper
• Ankaflavin regulates adipocyte function and attenuates hyperglycemia caused by high-fat diet via PPAR-γ activation

  2013cites this paper
• Thiazolidinediones in Type 2 Diabetes Mellitus

  2012cites this paper
• Changes of Peroxisome Proliferator-Activated Receptor-γ on Crushed Rat Sciatic Nerves and Differentiated Primary Schwann Cells

  2012cites this paper
• Effect of oat and milk based probiotic fermented product on type 2 diabetes.

  2012cites this paper
• Peroxisome Proliferator-Activated Receptor-γ

  2012cites this paper
• Beta Glucan: Health Benefits in Obesity and Metabolic Syndrome

  2011cites this paper
• The Monascus metabolite monascin against TNF-α-induced insulin resistance via suppressing PPAR-γ phosphorylation in C2C12 myotubes.

  2011cites this paper
• Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots.

  2010cites this paper
• Dietary fiber supplements: effects in obesity and metabolic syndrome and relationship to gastrointestinal functions.

  2010cites this paper
• Muscle-Derived Angiopoietin-Like Protein 4 Is Induced by Fatty Acids via Peroxisome Proliferator–Activated Receptor (PPAR)-δ and Is of Metabolic Relevance in Humans

  2009cites this paper
• REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY

  2009cites this paper
• Agonists at PPAR‐γ suppress angiotensin II‐induced production of plasminogen activator inhibitor‐1 and extracellular matrix in rat cardiac fibroblasts

  2008cites this paper
• Association between fatty acid binding protein 3 gene variants and essential hypertension in humans.

  2008cites this paper
• Short Insulin Tolerance Test Can Determine the Effects of Thiazolidinediones Treatment in Type 2 Diabetes

  2008cites this paper
• Duration of dietary linseed feeding affects the intramuscular fat, muscle mass and fatty acid composition in pig muscle

  2008cites this paper
• Effects of dietary fibers on disturbances clustered in the metabolic syndrome.

  2008cites this paper
• Hypoglycemic effects of exopolysaccharides produced by mycelial cultures of two different mushrooms Tremella fuciformis and Phellinus baumii in ob/ob mice

  2007cites this paper
• Insulin signaling and glucose transport in insulin resistant human skeletal muscle

  2007cites this paper
• Adipocyte fatty acid-binding protein (aP2), a newly identified LXR target gene, is induced by LXR agonists in human THP-1 cells

  2007cites this paper
• CLA isomers inhibit TNFalpha-induced eicosanoid release from human vascular smooth muscle cells via a PPARgamma ligand-like action.

  2006cites this paper
• Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione.

  2006cites this paper
• Rosiglitazone modifies the adipogenic potential of human muscle satellite cells

  2006cites this paper
• Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis.

  2006cites this paper
• Agoniści receptora PPARγ a zapobieganie powikłaniom sercowo-naczyniowym w cukrzycy typu 2. Wyniki badania PROactive The PPARγ receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study

  2006cites this paper
• PPARγ Ligand Troglitazone Lowers Cholesterol Synthesis in HepG2 and Caco-2 Cells via a Reduced Concentration of Nuclear SREBP-2

  2006cites this paper
• CLA isomers inhibit TNFα-induced eicosanoid release from human vascular smooth muscle cells via a PPARγ ligand-like action

  2006cites this paper
• Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists.

  2005cites this paper
• A method to establish co-cultures of myotubes and preadipocytes from collagenase digested neonatal pig semitendinosus muscles.

  2005cites this paper
• Adiponectin receptor gene expression in human skeletal muscle cells is not regulated by fibrates and thiazolidinediones

  2005cites this paper
• Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1

  2005cites this paper
• Role of PPARs in the Pathogenesis of the Metabolic Syndrome

  2005cites this paper
• Modulation of carbohydrate response element-binding protein gene expression in 3T3-L1 adipocytes and rat adipose tissue.

  2004cites this paper
• The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo.

  2004cites this paper
• Unliganded RXR acts as an inhibitory factor on troglitazone-induced activation.

  2004cites this paper
• The cellular fate of glucose and its relevance in type 2 diabetes.

  2004cites this paper
• Regulation of skeletal muscle peroxisome proliferator-activated receptor gamma expression by exercise and angiotensin-converting enzyme inhibition in fructose-fed hypertensive rats.

  2004cites this paper
• [Thiazolidinediones and insulin sensitivity].

  2004cites this paper
• New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists.

  2004cites this paper
• Effects of Rexinoids on Glucose Transport and Insulin-mediated Signaling in Skeletal Muscles of Diabetic (db/db) Mice*

  2004cites this paper
• Decreased expression of peroxisome proliferator activated receptor γ in CFTR−/− mice

  2004cites this paper
• Thiazolidinediones et insulino-sensibilit : rle du rcepteur nuclaire PPAR?

  2004cites this paper
• Nadciśnienie tętnicze a funkcja receptora aktywowanego przez proliferatory peroksysomów g Hypertension and a Function of Peroxisome Proliferator-Activated Receptor g

  2004cites this paper
• Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice.

  2004cites this paper
• Hydrogen peroxide overproduction in megamitochondria of troglitazone‐treated human hepatocytes

  2003cites this paper
• Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.

  2003cites this paper
• Thiazolidinediones: Potential Link Between Insulin Resistance and Cardiovascular Disease

  2003cites this paper
• Modulation of PPARγ activity with pharmaceutical agents: Treatment of insulin resistance and atherosclerosis

  2003cites this paper
• Síndrome de ovarios poliquísticos: abordaje diagnóstico y terapéutico

  2003cites this paper
• Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth.

  2003cites this paper
• Gamma (γ) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (γ) expression in SW 480 human colon cancer cell lines

  2003cites this paper
• Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD.

  2003cites this paper
• Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

  2003cites this paper
• Polymorphisms in fatty acid‐binding protein‐3 (FABP3) – putative association with type 2 diabetes mellitus

  2003cites this paper
• Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-&ggr; Agonist in Hypercholesterolemia

  2003cites this paper
• Insulin Resistant States and Insulin Signaling

  2003cites this paper
• PPAR agonists in health and disease: a pathophysiologic and clinical overview

  2002cites this paper
• PPARγ and the thiazolidinediones: molecular basis for a treatment of ‘Syndrome X’?

  2002cites this paper
• Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.

  2002cites this paper
• Prolonged dietary treatment with conjugated linoleic acid stimulates porcine muscle peroxisome proliferator activated receptor gamma and glutamine-fructose aminotransferase gene expression in vivo.

  2002cites this paper
• Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes.

  2002cites this paper
• The mode of action of thiazolidinediones

  2002cites this paper
• Novel insulin sensitizers: pharmacogenomic aspects.

  2002cites this paper
• Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes.

  2002cites this paper
• Troglitazone Downregulates Δ-6 Desaturase Gene Expression in Human Skeletal Muscle Cell Cultures

  2002cites this paper
• Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin.

  2002cites this paper
• Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis

  2002cites this paper
• Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.

  2002cites this paper
• Troglitazone downregulates delta-6 desaturase gene expression in human skeletal muscle cell cultures.

  2002cites this paper
• Ceramida como mediador de la resistencia a insulina producida por el factor de necrosis tumoral alfa en adipocitos marrones

  2002cites this paper
• Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.

  2002cites this paper
• Peroxisome proliferator-activated receptor gamma ligands differentially modulate muscle cell differentiation and MyoD gene expression via peroxisome proliferator-activated receptor gamma -dependent and -independent pathways.

  2001cites this paper
• Troglitazone induces GLUT4 translocation in L6 myotubes.

  2001cites this paper
• Unique Ability of Troglitazone to Up-Regulate Peroxisome Proliferator-Activated Receptor- (cid:1) Expression in Hepatocytes

  2001cites this paper
• Combined effects of troglitazone and muscle contraction on insulin sensitization in Balb-c mouse muscle.

  2001cites this paper
• Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle.

  2001cites this paper
• Troglitazone Induces GLUT 4 Translocation in L 6 Myotubes

  2001cites this paper
• PPAR gamma: an essential role in metabolic control.

  2001cites this paper
• Rosiglitazone

  2001cites this paper
• Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells.

  2001cites this paper
• Peroxisome proliferator-activated receptor gamma and metabolic disease.

  2001cites this paper
• Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.

  2001cites this paper
• Unique Ability of Troglitazone to Up-Regulate Peroxisome Proliferator-Activated Receptor- (cid:1) Expression in Hepatocytes

  2001cites this paper
• Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.

  2001cites this paper
• Survival activity of troglitazone in rat motoneurones

  2001cites this paper
• Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.

  2001cites this paper
• New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.

  2001cites this paper
• Preferential channeling of energy fuels toward fat rather than muscle during high free fatty acid availability in rats.

  2001cites this paper
• PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE

  2001cites this paper